BG62887B1 - Нафтиламиди като средства, повлияващи централната нервна система - Google Patents

Нафтиламиди като средства, повлияващи централната нервна система Download PDF

Info

Publication number: BG62887B1
Authority: BG; Bulgaria
Prior art keywords: ethyl; naphthalenecarboxamide; bromo; piperazinyl; methoxy
Prior art date: 1994-03-24

Application number

BG100830A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG100830A (en

Inventor

Shelly Glase

Suzanne Kesten

Lawrence WISE

Jonathan Wright

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-24

Filing date

1996-09-05

Publication date

2000-10-31

1996-09-05 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

1997-10-31 Publication of BG100830A publication Critical patent/BG100830A/xx

2000-10-31 Publication of BG62887B1 publication Critical patent/BG62887B1/bg

Links

210000003169 central nervous system Anatomy 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
201000009032 substance abuse Diseases 0.000 claims abstract description 4
231100000736 substance abuse Toxicity 0.000 claims abstract description 4
208000011117 substance-related disease Diseases 0.000 claims abstract description 4
208000024714 major depressive disease Diseases 0.000 claims abstract description 3
-1 hydroxy, amino Chemical group 0.000 claims description 62
150000001875 compounds Chemical class 0.000 claims description 59
150000003839 salts Chemical class 0.000 claims description 21
125000000217 alkyl group Chemical group 0.000 claims description 19
239000002253 acid Substances 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical class 0.000 claims description 13
229910052739 hydrogen Inorganic materials 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 12
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
125000003118 aryl group Chemical group 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 8
150000002431 hydrogen Chemical class 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
125000005309 thioalkoxy group Chemical group 0.000 claims description 6
208000028017 Psychotic disease Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
IRUKZAGWAZWZBI-UHFFFAOYSA-N 4-bromo-1-ethoxy-n-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]naphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OCC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=N1 IRUKZAGWAZWZBI-UHFFFAOYSA-N 0.000 claims description 2
COCBRLNWXSGWJZ-UHFFFAOYSA-N 4-bromo-1-methoxy-n-[2-(4-phenylpiperazin-1-yl)ethyl]naphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=C1 COCBRLNWXSGWJZ-UHFFFAOYSA-N 0.000 claims description 2
ZIVBQUNYSGOUKO-UHFFFAOYSA-N 4-bromo-1-methoxy-n-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]naphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=C1C ZIVBQUNYSGOUKO-UHFFFAOYSA-N 0.000 claims description 2
FVHHHZNMZQPIHB-UHFFFAOYSA-N 4-bromo-1-methoxy-n-[2-[4-(2-propylsulfanylphenyl)piperazin-1-yl]ethyl]naphthalene-2-carboxamide Chemical compound CCCSC1=CC=CC=C1N1CCN(CCNC(=O)C=2C(=C3C=CC=CC3=C(Br)C=2)OC)CC1 FVHHHZNMZQPIHB-UHFFFAOYSA-N 0.000 claims description 2
OSSGYBFCUFQSTI-UHFFFAOYSA-N 4-bromo-n-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=C1Cl OSSGYBFCUFQSTI-UHFFFAOYSA-N 0.000 claims description 2
SATOYXZJVAZVKU-UHFFFAOYSA-N 4-bromo-n-[2-[4-(3-chloro-2-methylphenyl)piperazin-1-yl]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC(Cl)=C1C SATOYXZJVAZVKU-UHFFFAOYSA-N 0.000 claims description 2
MCSZDZVTMAGPMA-UHFFFAOYSA-N 4-bromo-n-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC(Cl)=C1 MCSZDZVTMAGPMA-UHFFFAOYSA-N 0.000 claims description 2
UFTIBGSCHURYQF-UHFFFAOYSA-N 4-cyano-1-methoxy-n-[2-(4-phenylpiperazin-1-yl)ethyl]naphthalene-2-carboxamide Chemical compound C1=C(C#N)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=C1 UFTIBGSCHURYQF-UHFFFAOYSA-N 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
DKZINUPBBFMTAX-UHFFFAOYSA-N n-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-bromo-1-methoxynaphthalene-2-carboxamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCNC(=O)C3=C(C4=CC=CC=C4C(Br)=C3)OC)=NSC2=C1 DKZINUPBBFMTAX-UHFFFAOYSA-N 0.000 claims description 2
UNYSEHCMBKEYAW-UHFFFAOYSA-N n-[2-[4-(1-benzothiophen-3-yl)piperazin-1-yl]ethyl]-4-bromo-1-methoxynaphthalene-2-carboxamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCNC(=O)C3=C(C4=CC=CC=C4C(Br)=C3)OC)=CSC2=C1 UNYSEHCMBKEYAW-UHFFFAOYSA-N 0.000 claims description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
KDPMUYMEKOJROI-UHFFFAOYSA-N 4-bromo-1-methoxy-n-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]naphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC=N1 KDPMUYMEKOJROI-UHFFFAOYSA-N 0.000 claims 1
SQMUNKWOFRBGIX-UHFFFAOYSA-N 4-bromo-1-methoxy-n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1N1CCN(CCNC(=O)C=2C(=C3C=CC=CC3=C(Br)C=2)OC)CC1 SQMUNKWOFRBGIX-UHFFFAOYSA-N 0.000 claims 1
RAZKAAYRLZXGBT-UHFFFAOYSA-N 4-bromo-n-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl RAZKAAYRLZXGBT-UHFFFAOYSA-N 0.000 claims 1
KQOHKQXMRPXPAM-UHFFFAOYSA-N 4-bromo-n-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC(C)=C1C KQOHKQXMRPXPAM-UHFFFAOYSA-N 0.000 claims 1
XVXFMVGBYSVUIB-UHFFFAOYSA-N n-[2-[4-(1-benzofuran-7-yl)piperazin-1-yl]ethyl]-4-bromo-1-methoxynaphthalene-2-carboxamide Chemical compound C1=C(Br)C2=CC=CC=C2C(OC)=C1C(=O)NCCN(CC1)CCN1C1=CC=CC2=C1OC=C2 XVXFMVGBYSVUIB-UHFFFAOYSA-N 0.000 claims 1
JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 15
239000000164 antipsychotic agent Substances 0.000 abstract description 11
208000035475 disorder Diseases 0.000 abstract description 6
239000003795 chemical substances by application Substances 0.000 abstract description 4
230000003291 dopaminomimetic effect Effects 0.000 abstract description 3
239000003576 central nervous system agent Substances 0.000 abstract 1
229940125693 central nervous system agent Drugs 0.000 abstract 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
239000004480 active ingredient Substances 0.000 description 11
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229940005529 antipsychotics Drugs 0.000 description 8
239000002775 capsule Substances 0.000 description 8
230000000694 effects Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
102000004073 Dopamine D3 Receptors Human genes 0.000 description 6
108090000525 Dopamine D3 Receptors Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
239000005557 antagonist Substances 0.000 description 5
230000000561 anti-psychotic effect Effects 0.000 description 5
229960003638 dopamine Drugs 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
239000000203 mixture Substances 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000002585 base Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
101150097070 Drd3 gene Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
235000009508 confectionery Nutrition 0.000 description 3
239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
229940005501 dopaminergic agent Drugs 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
125000004356 hydroxy functional group Chemical group O* 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
230000004807 localization Effects 0.000 description 3
230000006742 locomotor activity Effects 0.000 description 3
230000010807 negative regulation of binding Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
CXDBJHMOQPPIJF-UHFFFAOYSA-N 2-[4-(2,3-dichlorophenyl)piperazin-1-yl]acetonitrile Chemical compound ClC1=CC=CC(N2CCN(CC#N)CC2)=C1Cl CXDBJHMOQPPIJF-UHFFFAOYSA-N 0.000 description 2
IVOGRWCTFYUYEN-UHFFFAOYSA-N 2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethanamine Chemical compound C1CN(CCN)CCN1C1=CC=CC(Cl)=C1Cl IVOGRWCTFYUYEN-UHFFFAOYSA-N 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000027455 binding Effects 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
108010024941 iodothyronine deiodinase type II Proteins 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
WRZJEVITDAEFCQ-UHFFFAOYSA-N 4-bromo-1-methoxynaphthalene-2-carboxylic acid Chemical compound C1=CC=C2C(OC)=C(C(O)=O)C=C(Br)C2=C1 WRZJEVITDAEFCQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
229940127333 Dopamine D2 Antagonists Drugs 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000002873 anti-autistic effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
238000009835 boiling Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
VUQFQRNHGGYQGK-UHFFFAOYSA-N n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1N1CCN(CCNC(=O)C=2C=C3C=CC=CC3=CC=2)CC1 VUQFQRNHGGYQGK-UHFFFAOYSA-N 0.000 description 1
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Liquid Carbonaceous Fuels (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Furan Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Quinoline Compounds (AREA)
Chemical And Physical Treatments For Wood And The Like (AREA)
Indole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

BG100830A 1994-03-24 1996-09-05 Нафтиламиди като средства, повлияващи централната нервна система BG62887B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/217,395 US5395835A (en)	1994-03-24	1994-03-24	Naphthalamides as central nervous system agents
PCT/US1995/001974 WO1995025727A1 (en)	1994-03-24	1995-02-16	Naphthylamides as central nervous system agents

Publications (2)

Publication Number	Publication Date
BG100830A BG100830A (en)	1997-10-31
BG62887B1 true BG62887B1 (bg)	2000-10-31

Family

ID=22810896

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG100830A BG62887B1 (bg)	1994-03-24	1996-09-05	Нафтиламиди като средства, повлияващи централната нервна система

Country Status (23)

Country	Link
US (1)	US5395835A (de)
EP (1)	EP0751939B9 (de)
JP (1)	JP3771581B2 (de)
KR (1)	KR100366175B1 (de)
AT (1)	ATE219068T1 (de)
AU (1)	AU683358B2 (de)
BG (1)	BG62887B1 (de)
CZ (1)	CZ284377B6 (de)
DE (1)	DE69527053T2 (de)
DK (1)	DK0751939T5 (de)
ES (1)	ES2178668T4 (de)
FI (1)	FI113370B (de)
HU (1)	HUT76058A (de)
MX (1)	MX9602517A (de)
NO (1)	NO306779B1 (de)
NZ (1)	NZ281824A (de)
PH (1)	PH31335A (de)
PL (1)	PL181270B1 (de)
PT (1)	PT751939E (de)
RO (1)	RO117452B1 (de)
RU (1)	RU2157370C2 (de)
WO (1)	WO1995025727A1 (de)
ZA (1)	ZA952382B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4425146A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Verwendung heterocyclischer Verbindungen
ATE211137T1 (de) *	1995-03-17	2002-01-15	Aventis Pharma Inc	Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung
FR2738569B1 (fr) *	1995-09-12	1997-11-28	Pf Medicament	Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique
US5659033A (en) *	1995-09-13	1997-08-19	Neurogen Corporation	N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
FR2742149B1 (fr) *	1995-12-11	1998-02-13	Inst Nat Sante Rech Med	Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
US5710274A (en) *	1996-02-28	1998-01-20	Neurogen Corporation	N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5703235A (en) *	1996-03-21	1997-12-30	Neurogen Corporation	N-Aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
US5763609A (en) *	1996-03-21	1998-06-09	Neurogen Corporation	Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703083A (en)	1996-04-15	1997-12-30	Neurogen Corporation	N-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
US5703237A (en) *	1996-04-18	1997-12-30	Neurogen Corporation	N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
US5688950A (en) *	1996-04-23	1997-11-18	Neurogen Corporation	Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
US5892041A (en) *	1996-08-12	1999-04-06	Neurogen Corporation	Fused indolecarboxamides: dopamine receptor subtype specific ligands
US6635642B1 (en)	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6346536B1 (en)	1997-09-03	2002-02-12	Guilford Pharmaceuticals Inc.	Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6197785B1 (en)	1997-09-03	2001-03-06	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en)	1997-09-03	2002-07-30	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
JP2002515488A (ja) *	1998-05-15	2002-05-28	ギルフォードファーマシューティカルズインコーポレイテッド	カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
US6395749B1 (en)	1998-05-15	2002-05-28	Guilford Pharmaceuticals Inc.	Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6387902B1 (en)	1998-12-31	2002-05-14	Guilford Pharmaceuticals, Inc.	Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US20030087917A1 (en) *	2000-03-27	2003-05-08	Dorothea Strack	Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
US6723733B2 (en)	2000-05-19	2004-04-20	Guilford Pharmaceuticals, Inc.	Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
AU2001275085A1 (en)	2000-06-01	2001-12-11	Guilford Pharmaceuticals Inc.	Methods, compounds and compositions for treating gout
US6545011B2 (en)	2000-07-13	2003-04-08	Guilford Pharmaceuticals Inc.	Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
WO2002066468A2 (en) *	2001-02-16	2002-08-29	Aventis Pharmaceuticals Inc.	Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
IL157412A0 (en) *	2001-02-16	2004-03-28	Aventis Pharmaceuticals Inc Av	Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
BR0306625A (pt) *	2002-05-23	2006-04-18	Abbott Lab	acetamidas e benzamidas que são úteis no tratamento de disfunção sexual
EP1593671A1 (de) *	2004-03-05	2005-11-09	Graffinity Pharmaceuticals AG	DPP-IV Inhibitoren
EP1870405A1 (de) *	2006-06-22	2007-12-26	Bioprojet	Carbonylierte (Aza)cyclohexane als Dopamin D3 Rezeptorliganden
KR20230001660U (ko)	2022-02-08	2023-08-16	주식회사 승진피엘에스	옷걸이용 지주 고정장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1543944A (fr) *	1967-03-10	1968-10-31	Bruneau & Cie Lab	Dérivés amidés de l'acide salicylique et leur préparation
US3846430A (en) *	1968-01-12	1974-11-05	Bruneau & Cie Lab	1-(2-methoxy-phenyl)-4-{8 2-(4-fluoro-benzamido)-ethyl{9 -piperazine
US4975439A (en) *	1987-09-25	1990-12-04	Janssen Pharmaceutical N.V.	Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5010078A (en) *	1988-05-24	1991-04-23	American Home Products Corporation	Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
IL90279A (en) *	1988-05-24	1995-03-30	American Home Prod	Piperazinyl carboxamide derivatives, their preparation and pharmaceutical com¦ositions containing them
JP2671059B2 (ja) *	1990-11-30	1997-10-29	富士レビオ株式会社	ナフトエ酸誘導体
FR2682953B1 (fr) *	1991-10-23	1995-04-21	Inst Nat Sante Rech Med	Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
SE9201138D0 (sv) *	1992-04-09	1992-04-09	Astra Ab	Novel phthalimidoalkylpiperazines
FR2693722B1 (fr) *	1992-07-16	1994-10-14	Meram Lab	Dérivés de la N-cycloalkylpipérazine, procédé d'obtention et compositions pharmaceutiques les contenant.
GB9218113D0 (en) *	1992-08-26	1992-10-14	Lilly Industries Ltd	Pharmaceutical compounds

1994
- 1994-03-24 US US08/217,395 patent/US5395835A/en not_active Expired - Fee Related
1995
- 1995-02-16 RU RU96119964/04A patent/RU2157370C2/ru not_active IP Right Cessation
- 1995-02-16 RO RO96-01853A patent/RO117452B1/ro unknown
- 1995-02-16 DE DE69527053T patent/DE69527053T2/de not_active Expired - Fee Related
- 1995-02-16 CZ CZ962768A patent/CZ284377B6/cs not_active IP Right Cessation
- 1995-02-16 DK DK95911021T patent/DK0751939T5/da active
- 1995-02-16 ES ES95911021T patent/ES2178668T4/es not_active Expired - Lifetime
- 1995-02-16 WO PCT/US1995/001974 patent/WO1995025727A1/en not_active Ceased
- 1995-02-16 JP JP52463695A patent/JP3771581B2/ja not_active Expired - Fee Related
- 1995-02-16 EP EP95911021A patent/EP0751939B9/de not_active Expired - Lifetime
- 1995-02-16 PL PL95316313A patent/PL181270B1/pl not_active IP Right Cessation
- 1995-02-16 HU HU9602605A patent/HUT76058A/hu unknown
- 1995-02-16 NZ NZ281824A patent/NZ281824A/en unknown
- 1995-02-16 MX MX9602517A patent/MX9602517A/es not_active IP Right Cessation
- 1995-02-16 PT PT95911021T patent/PT751939E/pt unknown
- 1995-02-16 AT AT95911021T patent/ATE219068T1/de not_active IP Right Cessation
- 1995-02-16 AU AU18774/95A patent/AU683358B2/en not_active Ceased
- 1995-02-16 KR KR1019960705267A patent/KR100366175B1/ko not_active Expired - Fee Related
- 1995-03-21 PH PH50161A patent/PH31335A/en unknown
- 1995-03-23 ZA ZA952382A patent/ZA952382B/xx unknown
1996
- 1996-08-23 FI FI963294A patent/FI113370B/fi not_active IP Right Cessation
- 1996-09-05 BG BG100830A patent/BG62887B1/bg unknown
- 1996-09-23 NO NO963996A patent/NO306779B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1995025727A1 (en)	1995-09-28
PL316313A1 (en)	1997-01-06
ES2178668T4 (es)	2003-06-16
EP0751939A1 (de)	1997-01-08
FI963294A0 (fi)	1996-08-23
NO963996D0 (no)	1996-09-23
HUT76058A (en)	1997-06-30
CZ284377B6 (cs)	1998-11-11
FI113370B (fi)	2004-04-15
MX9602517A (es)	1997-05-31
CZ276896A3 (en)	1997-04-16
EP0751939B1 (de)	2002-06-12
JPH09511503A (ja)	1997-11-18
RO117452B1 (ro)	2002-03-29
FI963294L (fi)	1996-08-23
NO963996L (no)	1996-09-23
KR100366175B1 (ko)	2003-04-08
EP0751939B9 (de)	2003-01-02
ES2178668T3 (es)	2003-01-01
BG100830A (en)	1997-10-31
AU683358B2 (en)	1997-11-06
AU1877495A (en)	1995-10-09
ATE219068T1 (de)	2002-06-15
DE69527053T2 (de)	2003-01-02
PH31335A (en)	1998-07-06
RU2157370C2 (ru)	2000-10-10
NZ281824A (en)	1997-10-24
NO306779B1 (no)	1999-12-20
DK0751939T3 (da)	2002-10-07
PT751939E (pt)	2002-11-29
HU9602605D0 (en)	1996-11-28
PL181270B1 (pl)	2001-07-31
US5395835A (en)	1995-03-07
ZA952382B (en)	1996-01-10
DK0751939T5 (da)	2004-11-08
DE69527053D1 (de)	2002-07-18
JP3771581B2 (ja)	2006-04-26

Publication	Publication Date	Title
BG62887B1 (bg)	2000-10-31	Нафтиламиди като средства, повлияващи централната нервна система
KR100443850B1 (ko)	2004-08-11	헤테로시클릭 화합물의 도파민-ｄ３ 리간드로서의 용도
JP2000504677A (ja)	2000-04-18	５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体
KR100343060B1 (ko)	2002-09-18	벤조푸릴유도체,이의제조방법및이를함유하는약제
US20040242589A1 (en)	2004-12-02	3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2012111784A (ja)	2012-06-14	置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用
FR2686878A1 (fr)	1993-08-06	Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
WO2004096767A1 (en)	2004-11-11	Sustituted indoline and indole derivatives
US6121267A (en)	2000-09-19	Substituted piperazines and piperidines as central nervous system agents
JP2003534331A (ja)	2003-11-18	置換１−アミノアルキルラクタム及びムスカリンレセプターアンタゴニストとしてのそれらの使用
JP2000516936A (ja)	2000-12-19	ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
JP2001512113A (ja)	2001-08-21	抗腫瘍及び抗転移剤としてのｏ−置換ヒドロキシクマラノン誘導体
WO2010040274A1 (zh)	2010-04-15	新型多巴胺d3受体配体，其制备方法及其医药用途
FI120400B (fi)	2009-10-15	Antineurodegeneratiivisesti vaikuttavat 10-aminoalifatyylidibents(b,f )oksepiinit
CN1063177C (zh)	2001-03-14	治疗偏头痛的吲哚烷基－吡啶基和嘧啶基哌嗪的1,2,5－噻二唑衍生物
GB2176785A (en)	1987-01-07	Annellated benzamide derivatives
JP2002509135A (ja)	2002-03-26	神経細胞カルシウムチャンネルの活性の調節剤としてのアミノスルホニルベンズアミド誘導体
AU3964393A (en)	1993-11-18	Novel amidoalkyl- and imidoalkyl-piperazines
JPS6257606B2 (de)	1987-12-02
CA2180155C (en)	2006-02-14	Naphthylamides as central nervous system agents
AU617094B2 (en)	1991-11-21	New indolecarboxamide derivatives as well as salts thereof, process and intermediates for preparation, application of these derivatives by way of medicinal products and compositions containing them
JPH11180979A (ja)	1999-07-06	環状アミン誘導体
AU597727B2 (en)	1990-06-07	Aryloxy-aminoalkanes
JP2002511450A (ja)	2002-04-16	４−アミノ−（エチルアミノ）−オキソインドールドパミン自己受容体作動薬
JPH02264780A (ja)	1990-10-29	α―アドレナリン作動性受容体拮杭剤